Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $56 to $51.
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $56 to $51.